Control charts diagnose endophthalmitis

Article

Control charts are an accurate way of measuring disparity in endophthalmitis following phacoemulsification, according to a study published online ahead of print by Eye.

Control charts are an accurate way of measuring disparity in endophthalmitis following phacoemulsification, according to a study published online ahead of print by Eye.

Patrick J. T. Chiam, MRCOphth of the Eye Department, Royal Dwent Hospital, Newport, UK and colleagues conducted a ten-year retrospective analysis of variety in post-cataract surgery endophthalmitis by applying the control chart method, using specified criteria to discern any deviations of the disease. During the study period (July 1 1997–June 30 2007), 21032 cataract surgeries were performed, with an endophthalmitis incidence of 0.16%.

The researchers found that, using control charts, it was possible reliably to detect endophthalmitis much earlier in the disease progression than symptom manifestation.

The team therefore concluded that the control chart method is a safe, reliable and sensitive way to determine postoperative endophthalmitis, particularly if there are any anomalies present.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.